Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: estatemakr who wrote (357)	11/2/2007 3:44:13 PM
From: NRugg	Read Replies (1) \| Respond to of 418

This is what the company said: "We continue to believe that CoFactor improves 5-FU-based chemotherapy and that, in the right indications and dosing regimens, CoFactor remains a viable product candidate. At this time, however, we feel that a partner for CoFactor would be better equipped to advance late stage development in first-line colorectal cancer, which represents the largest market opportunity but also the most costly and competitive clinical testing environment," said Evan Levine, chief executive officer of Adventrx." I don't think CoFactor has a great future as a substitute for leucovorin in injection treatment, together with 5_Fu, either by bolus or slow injection. The price difference with leucovorin to too large to compensate for any realistic expectation of reduced side effects. But I think that CoFactor may work with Xeloda as an oral drug to reduce the quantity of that drug needed and to also lower its side effects. Leucorvin has been tested that way and did not work to improve Xeloda. Lecorvorin has to be metabolized to work and CoFactor doesn't. The ideal way to combine these two would be in one pill, with a timed releae mechanization to optimize delivery, IMHO. Norman